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ABSTRACT ras oncogenes are mutated in a variety of
human tumors, which suggests that they play an important
role in human carcinogenesis. To determine whether contin-
ued oncogenic ras expression is necessary to maintain the
malignant phenotype, we studied the human fibrosarcoma cell
line, HT1080, which contains one mutated and one wild-type
N-ras allele. We isolated a variant of this cell line that no
longer contained the mutated copy of the N-ras gene. Loss of
mutant N-ras resulted in cells that displayed a less trans-
formed phenotype characterized by a flat morphology, de-
creased growth rate, organized actin stress fibers, and loss of
anchorage-independent growth. The transformed phenotype
was restored following reintroduction of mutant N-ras. Al-
though loss of the oncogenic N-ras drastically affected in vitro
growth parameters, the variant remained tumorigenic in nude
mice indicating that mutated N-ras expression is not necessary
for maintenance of the tumorigenic phenotype. We confirmed
this latter observation in colon carcinoma cell lines that have
lost activated K-ras expression via targeted knockout of the
mutant K-ras gene.
Mammalian Ras genes encode a family of plasma membrane-
bound proteins that function as intermediates in signal trans-
duction pathways involved in cell growth and differentiation.
ras oncogenes are frequently mutated in human cancer, which
suggests that they play a pivotal role in neoplastic transfor-
mation. Although studies of ras-mediated transformation led
to claims of "dominantly acting" oncogenes (1), it is now clear
that oncogenic ras expression is not sufficient to create the
malignant state in primary human cells (2-6) but may predis-
pose cells to transformation that occurs subsequent to other
independent events, such as ras amplification (6), other onco-
gene activation (7), or loss of function of tumor suppressor
genes (5). Even though oncogenic ras is not sufficient for
neoplastic transformation, its continued expression might be
necessary to maintain the malignant phenotype. Indeed, it has
been suggested that the "dominance" of oncogenes exists once
cells have undergone other genetic changes, such as loss of a
growth suppressor gene (8). It is obviously important to
determine whether ras has a direct role in maintaining the
neoplastic behavior of cancer cells. Tacit acceptance of the
notion of dominantly acting oncogenes is inherent in recent
research focusing on the development of anti-ras drugs for
cancer therapy (9-17).
To address whether oncogenic ras function is necessary for
maintenance of tumorigenicity in human tumor cells, we
exploited a variant of HT1080 human fibrosarcoma cells that
no longer expressed the endogenous mutated N-ras allele.
HT1080 cells are ideal for these studies because they have a
predominantly pseudodiploid karyotype and contain one nor-
mal and one mutated N-ras allele. This mutated allele results
from a point mutation at codon 61 that converts Gln61 to Lys61
(18). HT1080 cells are completely transformed in culture and
form progressively growing tumors in athymic mice. Further-
more, previous studies suggest that an absolute level of ex-
pression of the activated N-ras gene product controls the
tumor-forming capability of HT1080 cells in a dosage-
dependent manner (19). In this study, we report the effect of
loss of oncogenic N-ras on the transformed and tumorigenic
states of HT1080.
In addition, we have examined the oncogenic potential of
colon carcinoma cells that have lost mutant K-ras expression
as a consequence of targeted knockout of the relevant allele.
MATERIALS AND METHODS
HT1080 Cell Lines. The HT1080 variant, microcell hybrid
(MCH) 603c8, which lacks the activated N-ras allele, was
serendipitously isolated from a MCH fusion in the following
way. HT1080 6TG, a hypoxanthine phosphoribosyltransferase-
deficient variant of the HT1080 fibrosarcoma cell line (20, 21),
was used as a recipient in microcell-mediated chromosome
transfer experiments as described (22, 23). A Escherichia coli
guanine phosphoribosyl transferase-tagged chromosome 1,
containing the normal N-ras allele located at lpl3 (24) derived
from the parental HT1080 cell line (21), was transferred into
mouse A9 cells. The chromosome 1 subsequently was trans-
ferred from the donor A9 MCH into HT1080 6TG cells, and
MCHs containing the transferred chromosome were selected
in HAT (hypoxanthine/amethopterin/thymidine) medium
(25). Pseudodiploid hybrids that contained the extra trans-
ferred chromosome were studied in further detail.
Cytogenetic Analysis. Metaphase spread preparation and
Giemsa banding were performed as previously described (26).
Fluorescence in situ hybridization was performed as described
using a biotin-dUTP nick-translated chromosome 22 flow-
sorted library (27).
Restriction Fragment Length Polymorphism (RFLP) Anal-
ysis. Genomic DNA (16 ,g) was digested with BamHI, sep-
arated by 0.9% agarose gel electrophoresis, transferred to a
nitrocellulose membrane, and hybridized with radiolabeled
pMHZ14 (chromose lp probe; American Type Culture Col-
lection) as described (28).
Sequence Analysis. To sequence the N-ras gene encompass-
ing codon 61, PCR was performed using two primers specific
for the second -exon: 5'-primer, CAAGTGGTTATAGATG-
GTGA and 3'-primer, AGGAAGCCTTCGCCTGTCCT. The
110-bp PCR product was acrylamide gel-purified, subjected to
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asymmetric PCR as described (29), and sequenced directly
with Sequenase 2.0 kit (United States Biochemical).
Sequence determination of the three ras genes (N-, K-, and
H-) was carried out by reverse transcription (Moloney murine
leukemia virus; GIBCO/BRL) of extracted total RNA (30)
using oligo(dT) primers (GIBCO/BRL) and PCR amplifica-
tion of the region encompassing codons 12, 13, 59, and 61,
followed by cloning of the purified PCR product (Invitrogen).
Plasmid DNA from 100 pooled colonies was purified and
directly sequenced. The following primers were used for PCR:
N-ras, 5'-ATGACTGAGTACAAACTGGT and 3'-GAGG-
AAGCCTTCGCCTGTCCT; K-ras, 5'-CCTGCTGAAAAT-
GACTGAAT and 3'-AAATACACAAAGAAAGCCCT; and
H-ras, 5'-ATGACGGAATATAAGCTGGTG and 3'-ACT-
TGGTGTTGTTGATGGCAA. PCR amplification resulted in
250-, 255-, and 265-bp products, respectively.
N-ras cDNA Construction and in Vitro Mutagenesis. Wild-
type N-ras cDNA (pZIP-rasNwt4) was cloned into the BamHI
site of pCMVneo (31). Codon 61 (CAA; Glu) was mutated to
AAA (Lys) via plasmid site-directed mutagenesis (32) using
the primer TACAGCTGGAAAAGAAGAGTA to create the
plasmid pCMVneo-N-ras61K.
DNA Transfection. Subconfluent (70%) T75 flasks of MCH
603c8 were transfected overnight with 10 tkg of linearized
(HindIll) pCMVneo-N-ras61K DNA or vector control DNA
(pCMVneo) using 40 ,l of lipofectin (GIBCO/BRL) in Opti-
MEM medium (GIBCO/BRL). Clones were selected in me-
dium containing 800 ,ug of G418 (Sigma) per ml.
Western Blot Analysis. Cells from subconfluent six-well
dishes were lysed with 200 ,lI of RIPA buffer [150 mM NaCl,
1% Nonidet P-40, 0.4% deoxycholate, 0.1% SDS, 50 mM Tris
(pH 8), and 1 mM phenylmethylsulfonyl fluoride]. One hun-
dred and twenty micrograms of cellular lysate was electropho-
resed through a 12% SDS/polyacrylamide gel, and transferred
onto an Immobilon membrane (Millipore) as described (33).
Western blot analysis proceeded as described (34), using N-ras
primary antibody (F155; Santa Cruz Biotechnology), anti-
mouse IgG (horseradish peroxidase-conjugated) secondary
antibody (Santa Cruz Biotechnology), and enhanced chemi-
luminescence detection (Amersham).
Growth Kinetics. To assess growth kinetics under serum
conditions, cells (5 x 104) were seeded into duplicate T25
flasks containing DMEM/10% fetal calf serum (FCS). Flasks
were harvested on the indicated days and counted on a Coulter
counter. The medium was changed on day 4 and thereafter as
necessary. For serum starvation kinetic assays, cells (2 x 105)
were plated in DMEM/10% FCS in duplicate T25 flasks. The
next day the flasks were washed three times with DMEM with
no additives, and then refed with serum-free medium
(DMEM/F-12; 1:1) supplemented with sodium selenite (5
ng/ml), insulin (5 ,tg/ml), and transferrin (5 ,ug/ml), or
sodium selenite alone.
F-Actin Staining. Phalloidin staining was performed as
described (35, 36).
Soft Agar Growth. Cells (1 x 105 or 1 X 104) were seeded
in 0.3% top agar (in DMEM/10% FCS) above a 0.6% bottom
layer (in DMEM/10% FCS) in duplicate 60-mm plates as
described (37). Plates were fed periodically with 1 ml of
DMEM/10% FCS. Colonies were counted after 3 weeks.
Colon Carcinoma Cell Lines. The DLD-1 colon carcinoma
cell line, which is heterozygous for an activated K-ras allele and
variants which have lost the mutant allele or the wild-type
allele as a consequence of targeted knockout, were generated
by Shirasawa and colleagues (38).
Tumorigenicity Assays. Tumorigenicity was assessed by
subcutaneous injection of 1 x 107 cells, resuspended in 0.2 ml
of phosphate-buffered saline, into the flanks of 4- to 6-week-
old nude mice (three mice; two sites apiece for each cell line).
Tumors were measured in three dimensions with linear cali-
pers on the indicated days.
RESULTS
Oncogenic N-ras Influences Cell Morphology and Actin
Filament Organization. In previous studies, we showed that
the transfer of single copies of normal chromosome 1 via
microcell fusion had no effect on the transformed or tumor-
igenic phenotypes of parental HT1080 cells (39). In this study,
we transferred a copy of chromosome 1 derived from HT1080
cells, containing the wild type N-ras allele, into a hypoxanthine
phosphoribosyltransferase-deficient clone of HT1080
(HT1080 6TG) (data not shown). With one exception, all of the
HT1080 6TG/chromosome 1 MCH clones retained the trans-
formed and tumorigenic phenotypes of the parental HT1080
6TG cells. These each were found to contain an intact copy of
the transferred chromosome 1 (data not shown).
However, one clone, MCH 603c8, had a dramatically dif-
ferent phenotype in culture. This hybrid had a flat morphology
and reduced growth rate compared to the parental cell line.
Karyotypic analysis showed that the cell line contained two
intact copies of chromosome 1 and an unbalanced transloca-
tion involving the long arm of chromosome 1 (Fig. 1A). The
abnormal chromosome was identified as t(lq;22q) by fluores-
cent in situ hybridization using a 22-specific chromosome
library (data not shown). The translocation resulted in loss of
the short arm of the translocated chromosome 1. All other
chromosomal abnormalities detected were also present in the
parental HT1080 6TG cell line (Fig. lA). Therefore, this cell
line had a net increase in normal chromosome lq material, and
no net loss of chromosome lp material. To determine the
source of the chromosome 1 involved in the translocation, we
performed RFLP analysis using a probe specific for the distal
short arm of chromosome 1 (Fig. 1 B). The transferred chro-
mosome, containing the wild-type N-ras allele (represented by
the 14-kb band), was present in the donor A9/chromosome 1
MCH, the parental HT1080 6TG cell line, a MCH containing
an intact transferred chromosome 1 (MCH 603cl), and MCH
603c8. However, the copy of chromosome 1 containing the
mutated N-ras allele (represented by the 9-kb band) was
present in HT1080 6TG and MCH 603cl but was absent from
MCH 603c8 as well as the donor MCH. Sequence analysis of
the region surrounding codon 61, showed that MCH 603c8
contained only the wild-type codon 61 sequence (CAA) and
had lost the mutated copy (AAA; Fig. 1C). This confirmed
that the copy of the endogenous chromosome 1 containing the
mutant N-ras allele was involved in the translocation, resulting
in loss of the endogenous chromosome lp containing the
mutant allele.
To determine whether the altered morphology and reduced
in vitro growth rate of MCH 603c8 were due to loss of the
mutated N-ras allele, we reintroduced a mutant N-ras61K
cDNA, under the control of-the cytomegalovirus promoter,
into MCH 603c8 by liposome-mediated transfection. Western
blot analysis showed high expression of N-ras protein in
expressing clones (due to the transfected mutant form; Fig. 2,
lanes 3 and 4) as compared with the relatively low expression
in HT1080 6TG (mutant and wild-type) and MCH 603c8
(wild-type only; Fig. 2, lanes 1 and 2, respectively). Repeated
analyses showed that the total amount of N-ras protein was
similar in HT'1080 and MCH 603c8 cells (data not shown).
Vector control clones were obtained by transfection of MCH
603c8 with the vector (pCMVneo) lacking an N-ras gene.
The parental HT1080 6TG cell line had a rounded, more
refractile appearance upon light microscopic examination
(Fig. 3A), whereas MCH 603c8 had an elongated, flat mor-
phology (Fig. 3B). All vector control clones (V2-2 and V3-22)
retained the flat appearance (Fig. 3C), whereas expressing
mutant transfectants (M5-8 and M8-17; Fig. 3D) displayed a
more rounded morphology reminiscent of the parental cell
line.
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FIG. 1. Loss of the activated N-ras
allele in MCH 603c8. (A) Representative
GTG-banded karyotype. MCH 603c8 is
pseudodiploid and contains three abnor-
mal chromosomes [5p+, llq+, and
inv(7)] characteristic of the parental
HT1080 6TG cell line. The additional,
unique t(lq;22q) is indicated by an arrow.
(B) RFLP analysis of chromosome 1 in
MCH 603c8 with a probe specific for the
short arm of chromosome 1 (pMHZ14).
Lane 1, A9; lane 2, HT1080 6TG; lane 3,
MCH 6 m2b2 (donor A9/chromosome 1
hybrid); lane 4, MCH 603cl (contains an
intact transferred chromosome 1); and
lane 5, MCH 603c8. (C) Direct sequence
analysis. of the N-ras gene surrounding
codon 61.
In fibroblasts, actin stress fibers form a major part of the
cytoskeleton and are fused to the plasma membrane via focal
adhesions. Actin reorganization plays a role in cell motility and
cell shape, as well as in other cellular functions (40, 41). After
transformation, flat, well-spread, fibroblast-derived cells be-
come more round and display decreased cell-cell contact,
which is accompanied by a loss of actin stress fibers in the
cytoplasm and accumulation at the cell surface (ruffling; refs.
36 and 40). Membrane ruffling and stress fiber formation have
been linked to the ras-related proteins, rac and rho, respec-
tively (35, 36, 42). To determine the effect of loss of mutated
N-ras expression on actin stress fiber organization in HT1080
cells, we stained with fluorescein isothiocyanate-conjugated
phalloidin, which binds to filamentous F-actin (Fig. 3 E-H).
The parental HT1080 6TG cell line had few detectable actin
stress fibers under serum conditions (Fig. 3E), whereas MCH
603c8 had prominent stress fibers (Fig. 3F) reminiscent of
primary fibroblasts. Transfection of mutant N-ras into MCH
603c8 resulted in a return to the parental HT1080 6TG
1 2 3 4 5
_N-ras
FIG. 2. Expression of N-ras protein in HT1080 6TG-derived cell
lines. Western blot analysis using N-ras antibody that detects mutant
and wild-type protein. Lane 1, HT1080 6TG; lane 2, MCH 603c8; lane
3, M5-8; lane 4, M8-17; and lane 5, M5-8TR (tumor reconstitute of
M5-8).
phenotype (Fig. 3H), whereas vector controls retained the
stress fibers observed in MCH 603c8 (Fig. 3G).
Oncogenic N-ras Affects in Vitro Growth. MCH 603c8
displayed altered in vitro growth as compared with the parental
cell line. This was reflected in an increased doubling time and
decreased saturation density (Fig. 4A and Table 1). Mutant
transfectants grew more quickly than MCH 603c8 and had
doubling times and saturation densities comparable with
HT1080 6TG. Vector controls also grew slowly, with doubling
times approximating that observed for MCH 603c8 (Fig. 4A
and Table 1). Although MCH-603c8 and vector control clones
had lower saturation densities, they did not exhibit complete
contact inhibition.
Rodent cells transformed with ras oncogenes are able to
grow in serum-free medium and have a decreased dependence
on external growth factors, presumably because they secrete
autocrine growth factors (43, 44). To determine whether loss
of the activated N-ras results in HT1080 cells that are more
serum-dependcent, we cultured HT1080 6TG and MCH 603c8
under serum-free conditions, as well as supplemented with
insulin and transferrin. Certain transformed cells that secrete
autocrine growth factors are only able to grow in serum-free
medium supplemented with adjuvant factors (insulin and
transferrin; refs. 44 and 45). HT1080 6TG was able to grow
under serum-free conditions, and the addition of adjuvant
factors led to increased growth (data not shown). MCH 603c8
was able to divide in serum-free medium, but it grew at a
slower rate and achieved a much lower maximum cell density.
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FIG. 3. In vitro characteristics. Comparative morphology (A-D).
(A) HT1080 6TG, (B) MCH 603c8, (C) V2-2, and (D) M8-17. Actin
stress fiber organization illustrated by fluorescein isothiocyanate-
conjugated phalloidin staining of F-actin (E-H). (E) HT1080 6TG, (F)
MCH 603c8, (G) V2-2, and (H) M8-17. Magnification: phase-
contrast, x50; and fluorescein isothiocyanate fluorescence, x200.
(data not shown). Both cell lines were able to grow to a higher
maximum density when the medium was changed during the
course of the assay (Fig. 4B). However, MCH 603c8 reached
a maximum cell number and then began to die, whereas
HT1080 6TG did not achieve serum-free cell death when fed
regularly.
Mutant N-ras Controls The Capability For Anchorage-
Independent Growth. The HT1080-derived cell lines were
examined for their ability to display anchorage-independent
growth. HT1080 6TG formed large colonies in soft agar (Fig.
5A and Table 1), whereas MCH 603c8 did not form colonies
under the same conditions. Occasional colonies were observed
when the cells were seeded at high density (105 cells per 60-mm
dish; Fig. 5B). Vector control clones were all unable to grow
in soft agar (Fig. SC and Table 1). Mutant transfectants did not
grow in soft agar when seeded at low density (Table 1), but
formed numerous large colonies at high density (Fig. SD).
Oncogenic N-ras Does Not Control Tumor-Forming Ability.
In vivo tumorigenic potential was assessed by subcutaneous
injection of the cell lines into the flanks of athymic nude
(nu/nu) mice. HT1080 6TG formed aggressive tumors with no
latency period (Fig. 6A). MCH 603c8 also formed tumors with
no latency period, as did the vector control. However, these
tumors grew at a slower rate than HT1080 6TG (Fig. 6A) but
eventually reached the size of the tumors observed from the
parental cell line. A smaller inoculum (1 x 106 cells) of
FIG. 4. In vitro growth kinetics. (A) Growth kinetics under serum
conditions. (B) Serum deprivation growth kinetics. Flasks were fed on
days 4, 7, and 10 (filled symbols), or were not fed at all during the
course of the study (open symbols).
HT10806T6 and MCH 603c8 were also injected subcutane-
ously. Again, tumors formed in all animals. The lag period was
longer for both cell lines, and again the MCH603c8 cells
formed tumors more slowly than HT1080 6TG (data not
shown). Lower numbers of cells were not inoculated, because
in previous experiments we had found that at a dose of 5 x 105
cells, HT1080 6TG formed tumors in only a fraction of animals
and the incidence of tumor formation was variable (E.J.S.,
unpublished observations). Histologic examination of excised
MCH 603c8 tumors showed fibrosarcomas containing some
necrotic tissue. Codons 12, 13, 59, and 61 of N-ras, K-ras, and
H-ras genes were sequenced in tumor reconstitutes from MCH
603c8 and were found to remain wild-type, indicating that its
ability to form tumors could not be explained by a de novo ras
mutation (data not shown). Furthermore, tumor reconstitutes
from MCH 603c8 had no additional cytogenetic abnormalities,
and reinoculation of these tumor reconstitutes gave similar
kinetics of tumor formation (data not shown). N-ras mutant
transfectant (M5-8 and M8-17) tumors grew as aggressively as
the parental HT1080 6TG cell line (Fig. 6A), retained a
rounded morphology, and continued to express the mutant
N-ras protein at a high level (Fig. 2, lane 5).
Colon Carcinoma-Mutant K-ras Does Not Control Tumor
Formation. Shirasawa et al. (38) have reported that disruption
of the mutant K-ras allele from human colon carcinoma cell
lines results in-loss of tumor-forming ability. Because of the
differences in our results we obtained representative cell lines
and examined their tumorigenic properties using the same
inoculum size (1 X 107 cells per site) reported by the authors.
In contrast to the published studies, we found that the two cell
lines with a disrupted mutant K-ras allele (DKO3 and DKs8)
were tumorigenic (Fig. 6B). As with MCH 603c8, they formed
tumors more slowly than the parental DLD-1 colon carcinoma
cells but eventually reached the same volume. Sequencing of
the tumor reconstitutes showed no mutations in any of the N-,
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Table 1. Growth properties of HT1080 6TG-derived cell lines
Actin stress Doubling Saturation Growth in
Cell line Morphology fibers time,* hr density,t X 106 soft agar,: % Tumorigenicity§
HT1080 6TG Round - 22.8 24 23 18/18
MCH 603c8 Flat + 33.6 9 0.08 16/18
V2-2 (vector) Flat + 36.0 5.3 0.025. 6/6
V3-22 (vector) Flat + 38.4 5.3 0.55 6/6
M5-8 (mutant) Round - 24.0 17 0.1 6/6
M8-17 (mutant) Round - 26.4 18 0.045 6/6
*The number of hours required to produce one population doubling as determined from the linear portion of each curve
averaged from two separate experiments.
tThe highest number reached after cells became confluent. The number represents the average from two growth curves.
tEach value represents the average of the percent of 1 x 104 cells that form colonies >0.1 mm, in duplicate 60-mm plates from
two separate experiments.
§The fraction of mice with tumors after 2 months.
DISCUSSION
Loss of the mutant N-ras allele from HT1080 cells led to dramatic
phenotypic changes, such as a flat morphology, appearance of
organized actin stress fibers, and loss of anchorage-independent
growth. These growth changes were only observed in the variant
cell line that had lost the activated N-ras allele and were not
observed in MCH clones containing an extra intact chromosome
1. These data show that the growth changes observed in our
variant were not due to the net increase in normal chromosome
lq material in the cell line. In addition, reintroduction of the
mutant N-ras into the variant led to reversion to the parental cell
line morphology, actin filament organization, and in vitro and in
vivo growth rates, suggesting that the oncogenic N-ras was
responsible for the growth changes observed in the variant cell
line. In the case of anchorage-independent growth, reintroduc-
tion of the mutant N-ras resulted in colony formation only at high
cell density, and the mutant was not able to completely revert the
phenotype. The reason for this observation is not known but may
reflect differences due to the significantly higher level of expres-
sion of mutant N-ras in the transfectants compared to endoge-
nous levels in the parental HT1080 6TG.
Our data show that like H-ras, oncogenic N-ras also plays an
important role in controlling neoplastic cell shape and the
cytoskeleton possibly by a rac- and/or rho-dependent pathway
(35, 36, 42). Loss of oncogenic N-ras also resulted in cells that
proliferated at a slower rate and had a diminished capacity to
grow under serum-free conditions. ras is known to be involved
in multiple signal transduction pathways, such as that involving
the Raf/mitogen-activated protein kinase kinase/mitogen-
activating protein kinase cascade (for review see ref. 46).
FIG. 5. Anchorage-independent growth. (A) HT1080 6TG, (B)
MCH 603c8, (C) V2-2, and (D) M8-17. Phase-contrast magnification,
X50.
Constitutive ras expression, which occurs when cells contain an
oncogenic ras allele, as in the parental HT1080 6TG cells, may
lead to constitutive activation of kinases in the pathways,
resulting in cell proliferation in the absence of external mito-
genic stimulation. Loss of oncogenic ras expression could
cause reversion to a regulated growth pathway, which may
explain the slower in vitro and in vivo growth and decreased
saturation density observed in MCH 603c8. However, MCH
603c8, despite loss of the mutant ras allele, still had a limited
capability for serum-free growth. This may be because HT1080
and MCH 603c8 produce a growth factor (platelet-derived
growth factor) that allows them to survive under serum-free
conditions independent of ras status (47). The presence of a
mutated N-ras allele may enhance the ability for serum-free
growth, possibly due to the secretion of additional factors. We
currently are in the process of investigating ras and platelet-
derived growth factor signal transduction in these cells.
Although loss of the oncogenic ras allele resulted in altered
morphology and growth kinetic changes possibly mediated by
various signal transduction pathways, MCH 603c8 remained
tumorigenic in nude mice. We are well aware that MCH 603c8
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FIG. 6. In vivo growth kinetics. (A) HT1080 6TG-derived cell lines.
(B) DLD-1-derived cell lines.
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experimental model. However, several criteria suggest that this
is a bona fide observation. Multiple MCH clones of HT1080
6TG containing an extra intact chromosome 1 have no effect
on in vitro or in vivo growth (39). Thus, the extra lq material
in MCH 603c8 is not responsible for its phenotype. It might be
argued that the translocation t(lq;22q) chromosome is critical.
However, transfection of mutant N-ras cDNA into these cells
restores the original HT1080 phenotype in multiple clones. It
is possible, but highly unlikely, that de novo events (not involving
ras mutations) are responsible for the tumorigenic phenotype of
MCH 603c8 and the multiple subclones generated by vector
transfection. To accommodate such a phenomenon, one would
have to infer significant genomic instability in MCH 603c8,
allowing for in vivo selection of tumorigenic variants. Classically,
this is seen as a long latent period followed by rapid growth in vivo.
Subsequent tumor reconstitutes then grow rapidly when rein-
jected in the host animal. We did not observe this phenome-
non. MCH 603c8 and its vector transfectants form tumors
more slowly than the parental HT1080 6TG and retain these
kinetics of tumor formation after reinjection.
Similar results were obtained with the colon carcinoma
DLD-1-derived cell lines. It is unclear, at this time, why there
is a discrepancy between our tumorigenicity data and those
reported by Shirasawa et al. (38). Sequence analysis shows that
the cell lines and tumor reconstitutes do not contain any
mutated ras genes, thereby ruling out any in vitro ras mutations.
The tumorigenicity assays were performed in the same manner
using the same amount of inoculum.
Thus the summation of these studies argues strongly that loss
of mutant ras function has significant effects on in vitro and in
vivo growth and morphologic parameters but does not abro-
gate tumor growth.
The results of our research are important in light of recent
studies in the field of anti-ras cancer therapy, such as the use
of anti-ras antibodies (9), anti-ras ribozymes (13), anti-sense
ras strategies (11, 12), and inhibitors of ras function (farnesyl
transferase inhibitors; refs. 14-17). If ras is not necessary to
maintain tumorigenicity in human cells, as our study suggests,
anti-ras therapies might not be effective treatments for cancer.
Preliminary results regarding anti-ras therapies initially ap-
peared promising. However, a close examination of the re-
search shows that most studies used rodent rather than human
cells (9, 12-14) and, with one exception (17), those that used
human cells did not test the treatment in tumorigenicity assays
(15, 16). Nagusa et al. (17), in their study of a farnesyl
transferase inhibitor, treated nude mice injected with human
cell lines. However, the inhibitor appeared to have little or no
effect on the tumor growth rates in two out of three cell lines
tested, including the HT1080 cell line (17). Further experi-
mentation with human cells is clearly warranted to determine
the efficacy of anti-ras therapies.
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